Coronary/Structural Heart

Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers – – Launch Date Accelerated by One Month at Health Care Providers Request […]

Neovasc Reducer Spotlighted in Leading German Public Television Program

Elective Interventional Procedures Resume in Germany VANCOUVER and MINNEAPOLIS, MN, June 03, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced […]

Heart Valve Voice Canada Calls for the Prioritization of Heart Valve Disease Patients as Elective Surgeries Begin to Resume

TORONTO, June 03, 2020 (GLOBE NEWSWIRE) — Heart Valve Voice (HVV) Canada, a non-profit patient advocacy organization for those with heart valve disease, urges provincial governments and health care institutions to prioritize the treatment of heart valve disease patients as elective surgeries are reassessed and begin to resume during COVID-19. […]

Teleflex Announces First Patient Enrollment in CTO-PCI IDE Study

Study Will Evaluate the Performance of Teleflex Coronary Guidewires and Specialty Catheters in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions WAYNE, Pa., June 02, 2020 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical study […]

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

First-of-its-kind study evaluates ultra-short DAPT in PCI patients at high bleeding risk compared to drug-eluting stents SAN ANTONIO, June 1, 2020 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced that it has successfully completed enrollment […]

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure

DANVERS, Mass.–(BUSINESS WIRE)–The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. Impella RP is a temporary heart pump that provides circulatory support for […]

Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education

Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced that it intends to increase the level and breadth of […]

Resverlogix Plans COVID-19 Clinical Trial Program Launch

Epigenetic BET-inhibition to combat COVID-19 CALGARY, Alberta, June 01, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate apabetalone’s impact on COVID-19 in both a preclinical and clinical setting. A first step will be to […]

BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

New BRILINTA indication expands treatment to high-risk coronary patients without a history of stroke or heart attack WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s BRILINTA® (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of […]

Foldax Wins 2020 MedTech Breakthrough Award for Cardiovascular Technology Innovation

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected its Tria™ LifePolymer™ heart valve technology […]